The State Food and Drug Administration approved the registration application of domestic new coronary pneumonia treatment drugs with conditions

The State Food and Drug Administration approved Henan Biotechnology on the 25th in accordance with the special approval procedure Co., Ltd. Azvudine Tablets added registration applications for the treatment of new coronavirus pneumonia. The drug is an oral small molecule novel coronavirus pneumonia treatment drug independently developed by my country. On July 20, 2021, the State Food and Drug Administration has conditionally approved the drug in combination with other reverse transcriptase inhibitors to treat adult HIV-1 infected patients with high viral load. This is a conditional approval of an additional indication for the treatment of adult patients with common novel coronavirus pneumonia. Patients should strictly follow the instructions for medication under the guidance of a physician. The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in a timely manner.

Source: Xinhuanet(ID: newsxinhua) comprehensive Xinhua News Agency, National Drug Administration website

Producer: Chen Dong

Editor: Li Huiping p>

Recommended reading

  • @Car owner, domestic oil prices may drop for three consecutive times tomorrow night! In some areas, No. 95 gasoline is expected to return to the “8 yuan era”

  • The Ministry of Public Security responded to the incident of beating people in Tangshan barbecue restaurant

  • 5.5G adds innovative power to the information age